NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?

ABSTRACT Neuraminidase is one of the two surface glycoproteins of influenza A and B viruses. It has enzymatic activity that cleaves terminal sialic acid from glycans, and that activity is essential at several points in the virus life cycle. While neuraminidase is a major target for influenza antivir...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Florian Krammer, Ron A. M. Fouchier, Maryna C. Eichelberger, Richard J. Webby, Kathryn Shaw-Saliba, Hongquan Wan, Patrick C. Wilson, Richard W. Compans, Ioanna Skountzou, Arnold S. Monto
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2018
Materias:	influenza vaccines neuraminidase universal influenza virus vaccine Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/3f64edeb94884879b50fdc42041b2317
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3f64edeb94884879b50fdc42041b2317
record_format	dspace
spelling	oai:doaj.org-article:3f64edeb94884879b50fdc42041b23172021-11-15T15:53:27ZNAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?10.1128/mBio.02332-172150-7511https://doaj.org/article/3f64edeb94884879b50fdc42041b23172018-05-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.02332-17https://doaj.org/toc/2150-7511ABSTRACT Neuraminidase is one of the two surface glycoproteins of influenza A and B viruses. It has enzymatic activity that cleaves terminal sialic acid from glycans, and that activity is essential at several points in the virus life cycle. While neuraminidase is a major target for influenza antivirals, it is largely ignored in vaccine development. Current inactivated influenza virus vaccines might contain neuraminidase, but the antigen quantity and quality are varied and not standardized. While there are data that show a protective role of anti-neuraminidase immunity, many questions remain unanswered. These questions, among others, concern the targeted epitopes or antigenic sites, the potential for antigenic drift, and, connected to that, the breadth of protection, differences in induction of immune responses by vaccination versus infection, mechanisms of protection, the role of mucosal antineuraminidase antibodies, stability, and the immunogenicity of neuraminidase in vaccine formulations. Reagents for analysis of neuraminidase-based immunity are scarce, and assays are not widely used for clinical studies evaluating vaccines. However, efforts to better understand neuraminidase-based immunity have been made recently. A neuraminidase focus group, NAction!, was formed at a Centers of Excellence for Influenza Research and Surveillance meeting at the National Institutes of Health in Bethesda, MD, to promote research that helps to understand neuraminidase-based immunity and how it can contribute to the design of better and broadly protective influenza virus vaccines. Here, we review open questions and knowledge gaps that have been identified by this group and discuss how the gaps can be addressed, with the ultimate goal of designing better influenza virus vaccines.Florian KrammerRon A. M. FouchierMaryna C. EichelbergerRichard J. WebbyKathryn Shaw-SalibaHongquan WanPatrick C. WilsonRichard W. CompansIoanna SkountzouArnold S. MontoAmerican Society for Microbiologyarticleinfluenza vaccinesneuraminidaseuniversal influenza virus vaccineMicrobiologyQR1-502ENmBio, Vol 9, Iss 2 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	influenza vaccines neuraminidase universal influenza virus vaccine Microbiology QR1-502
spellingShingle	influenza vaccines neuraminidase universal influenza virus vaccine Microbiology QR1-502 Florian Krammer Ron A. M. Fouchier Maryna C. Eichelberger Richard J. Webby Kathryn Shaw-Saliba Hongquan Wan Patrick C. Wilson Richard W. Compans Ioanna Skountzou Arnold S. Monto NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
description	ABSTRACT Neuraminidase is one of the two surface glycoproteins of influenza A and B viruses. It has enzymatic activity that cleaves terminal sialic acid from glycans, and that activity is essential at several points in the virus life cycle. While neuraminidase is a major target for influenza antivirals, it is largely ignored in vaccine development. Current inactivated influenza virus vaccines might contain neuraminidase, but the antigen quantity and quality are varied and not standardized. While there are data that show a protective role of anti-neuraminidase immunity, many questions remain unanswered. These questions, among others, concern the targeted epitopes or antigenic sites, the potential for antigenic drift, and, connected to that, the breadth of protection, differences in induction of immune responses by vaccination versus infection, mechanisms of protection, the role of mucosal antineuraminidase antibodies, stability, and the immunogenicity of neuraminidase in vaccine formulations. Reagents for analysis of neuraminidase-based immunity are scarce, and assays are not widely used for clinical studies evaluating vaccines. However, efforts to better understand neuraminidase-based immunity have been made recently. A neuraminidase focus group, NAction!, was formed at a Centers of Excellence for Influenza Research and Surveillance meeting at the National Institutes of Health in Bethesda, MD, to promote research that helps to understand neuraminidase-based immunity and how it can contribute to the design of better and broadly protective influenza virus vaccines. Here, we review open questions and knowledge gaps that have been identified by this group and discuss how the gaps can be addressed, with the ultimate goal of designing better influenza virus vaccines.
format	article
author	Florian Krammer Ron A. M. Fouchier Maryna C. Eichelberger Richard J. Webby Kathryn Shaw-Saliba Hongquan Wan Patrick C. Wilson Richard W. Compans Ioanna Skountzou Arnold S. Monto
author_facet	Florian Krammer Ron A. M. Fouchier Maryna C. Eichelberger Richard J. Webby Kathryn Shaw-Saliba Hongquan Wan Patrick C. Wilson Richard W. Compans Ioanna Skountzou Arnold S. Monto
author_sort	Florian Krammer
title	NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
title_short	NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
title_full	NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
title_fullStr	NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
title_full_unstemmed	NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
title_sort	naction! how can neuraminidase-based immunity contribute to better influenza virus vaccines?
publisher	American Society for Microbiology
publishDate	2018
url	https://doaj.org/article/3f64edeb94884879b50fdc42041b2317
work_keys_str_mv	AT floriankrammer nactionhowcanneuraminidasebasedimmunitycontributetobetterinfluenzavirusvaccines AT ronamfouchier nactionhowcanneuraminidasebasedimmunitycontributetobetterinfluenzavirusvaccines AT marynaceichelberger nactionhowcanneuraminidasebasedimmunitycontributetobetterinfluenzavirusvaccines AT richardjwebby nactionhowcanneuraminidasebasedimmunitycontributetobetterinfluenzavirusvaccines AT kathrynshawsaliba nactionhowcanneuraminidasebasedimmunitycontributetobetterinfluenzavirusvaccines AT hongquanwan nactionhowcanneuraminidasebasedimmunitycontributetobetterinfluenzavirusvaccines AT patrickcwilson nactionhowcanneuraminidasebasedimmunitycontributetobetterinfluenzavirusvaccines AT richardwcompans nactionhowcanneuraminidasebasedimmunitycontributetobetterinfluenzavirusvaccines AT ioannaskountzou nactionhowcanneuraminidasebasedimmunitycontributetobetterinfluenzavirusvaccines AT arnoldsmonto nactionhowcanneuraminidasebasedimmunitycontributetobetterinfluenzavirusvaccines
_version_	1718427209790652416

NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?

Ejemplares similares